TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05541146

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Description: Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
Study: NCT05915845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laura Mitchell's Relaxation technique
Description: This technique was used to eliminate muscular tension. Patients were taught to contract muscles opposite to the strained muscle groups, eventually to 'cease' shrunken them, and then to roster the position adaptation of the body structure. Patient was comfortably positioned.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Papworth exercise
Description: The Papworth Method integrates five components, the principal one being specific breathing training:~• Breathing training, including teaching of appropriate minute and tidal volume and the development of a pattern of breathing suitable to current metabolic activity.~Elimination of dysfunctional breathing, including hyperinflation and hyperventilation patterns is discussed. A specific Papworth method diaphragmatic breathing technique is taught to replace the use of inappropriate accessory muscles of respiration. When relaxed, is placed on calm slow nasal expiration. Patients are encouraged to nose-breathe rather than mouth-breathe and eradication or reduction of habits such as yawning, sighing, etc. is taught and practiced.
Study: NCT05686785

Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Transient elastography measures liver stiffness in kPa
Study: NCT06243692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 50Mg Tab
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study: NCT06063174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program
Description: 12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Well Program
Description: 12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Well Program
Description: 12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Well Program
Description: 12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Well Program
Description: 12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
Study: NCT05229042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ricolinostat
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ricolinostat
Description: Oral
Study: NCT05197725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: Individuals in intervention communities will be given surgical or KF94 face masks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face mask awareness
Description: Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face mask promotion through community values or individual information
Description: In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)
Study: NCT04679480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab Injection [Libtayo]
Description: Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial.
Study: NCT05949294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-SOD1 Injection
Description: single doses of ARO-SOD1 Injection by IT infusion
Study: NCT04292184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%
Description: The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
Study: NCT05908045

Intervention type: OTHER
Intervention: KAP Survey
Description: This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
Study: NCT05811390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: erythritol jet
Description: Use of an erythritol jet in the non-surgical treatment of periimplantitis together with systemic metronidazole

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual instrumentation
Description: Use of manual instrumentation in the non-surgical treatment of periimplantitis together with systemic metronidazole
Study: NCT04678115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Levator Prosthesis (MLP)
Description: Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Levator Prosthesis (MLP)
Description: Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape Frontalis Sling (KTFS)
Description: Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape Frontalis Sling (KTFS)
Description: Kineso Tape is FDA registered as a 510K exempt class 1 device, typically used by physical and occupational therapist to support muscular healing and movement. It is sometimes used on the face in cases of facial palsy or on the eye lid to support the lid in cases of severe blepharoptosis. In such cases it may be attached near the lid margin above the lashes extending up to the forehead skin overlying the frontalis muscle. Alternatively it may be a very short piece attached only along the lid skin. The tape is easily removed.
Study: NCT06063174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move Well Program
Description: 12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
Study: NCT06096454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: effect of life style modification and metformin on hypothyroidism with insulin resistance
Study: NCT05004896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: 50 patients will receive ketamine hydrochloride, over four infusions, flexibly dosed between 0.5 mg/kg to 0.75 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride
Description: 50 patients will receive midazolam hydrochloride, over four infusions, flexibly dosed between 0.02 mg/kg to 0.03 mg/kg
Study: NCT05366790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEASE and CEASE-A
Description: CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
Study: NCT06529510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink therpeutic game
Description: REThink is an online therapeutic game aimed at enhancing the emotional health of young people, grounded in Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who guides players through seven levels, each focused on teaching a specific emotional regulation skill. Each level has three sub-levels that progressively increase in difficulty. REThink can be used as a standalone intervention, an adjunct to self-help psychotherapeutic approaches, or for targeted skills training.
Study: NCT05655663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular investigation
Description: Measure of of carotid stiffness
Study: NCT05322252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200mg orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Per clinician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Per clinician
Study: NCT05626166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin
Description: diosmin 600 mg twice daily
Study: NCT05272371

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
Description: Dinutuximab beta in combination with chemotherapy.
Study: NCT01222013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
Study: NCT05777044

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participation in Hatha Yoga twice a week for 45 minutes for 10 weeks. The total potential dose is 900 minutes over the course of the intervention.
Study: NCT04908085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching
Description: Six sessions of OPC delivered by telephone over 10 weeks.
Study: NCT04419831

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
Study: NCT05510063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira (Adalimumab)
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira (Adalimumab)
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB5 (Adalimumab Biosimilar)
Description: Subcutaneous (SC) injection
Study: NCT05117736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
Study: NCT06366178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BONFIX system
Description: The device corresponds to a customized, single-use surgical guide (Class IIa medical device), with a set of different sizes, adapted to the fronto-zygomatic distance (FDZ) measurement, in order to enable better conformation of the orbito-naso-frontal bandeau during surgery for anterior craniostenosis, an ideal conformation that could lead to optimal symmetry and adapted to the morphology of the upper third of infants.~The surgeon conforms the orbito-naso-frontal bandeau by adapting the advancement between the device supports according to the FDZ and then positioning it directly on the surgical guide.
Study: NCT05833958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin
Description: As described previously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As described previously - Experimental Arm, 175mg at night

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
Study: NCT05512754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: 400 mg tablet
Study: NCT04470518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic algorithm
Description: Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache \& Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor)).
Study: NCT06073613

Intervention type: DIAGNOSTIC_TEST
Intervention: oral health status
Description: * CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,...) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions

Intervention type: DIAGNOSTIC_TEST
Intervention: oral health status
Description: * CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,...) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions
Study: NCT06361563

Intervention type: DRUG
Intervention: Nivolumab
Description: As per product label
Study: NCT05862909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHD-specific web-based emotion regulation intervention
Description: CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General web-based emotion regulation intervention
Description: General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
Study: NCT05142488

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Covid -19 (recombinante) vaccine
Description: Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid -19 (recombinante) vaccine
Description: Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
Study: NCT05878834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan supplement group
Description: Take 1 capsule 1 time per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Take 1 capsule 1 time per day for 12 weeks.
Study: NCT05457465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Custom formulation of a hemp-derived, high-CBD product that contains no THC.
Study: NCT05909852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501-HCF
Description: Participants will receive a single-dose SC injection of ABP 501-HCF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501-LCF
Description: Participants will receive a single-dose SC injection of ABP 501-LCF
Study: NCT04718207

Intervention type: DEVICE
Intervention: Brain positron emission tomopgraphy (PET) - scan
Description: Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
Study: NCT05507307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based pregnancy education program.
Description: Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
Study: NCT05470335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nurse-led sheath insertion
Description: radial sheaths for coronary examination and intervention are performed by experienced nurses